← Back to Screener
Innate Pharma S.A. ADS (IPHA)
Price$1.71
Value ScoreD
Growth ScoreF
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-19.82%
Price vs S&P 500 (4W)22.04%
VGM Score30.41
Market Capitalization$168.76M
All Metrics
Book Value / Share (Quarterly)$0.06
P/TBV (Annual)18.20x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-61.69%
Cash Flow / Share (Quarterly)$-0.65
Price vs S&P 500 (YTD)-11.23%
Gross Margin (TTM)0.81%
Net Profit Margin (TTM)-1103.12%
EPS (TTM)$-0.63
10-Day Avg Trading Volume0.37M
EPS Excl Extra (TTM)$-0.63
Revenue Growth (5Y)-45.15%
EPS (Annual)$-0.63
ROI (Annual)-124.21%
Gross Margin (Annual)1.29%
Net Profit Margin (5Y Avg)-544.85%
Cash / Share (Quarterly)$0.42
Revenue Growth QoQ (YoY)-35.62%
ROA (Last FY)-78.41%
Revenue Growth TTM (YoY)-64.68%
EBITD / Share (TTM)$-0.68
ROE (5Y Avg)-154.41%
Operating Margin (TTM)-1211.48%
Cash Flow / Share (Annual)$-0.65
P/B Ratio28.37x
P/B Ratio (Quarterly)27.27x
Net Income / Employee (Annual)$-346,832
EV / Revenue (TTM)31.50x
Net Interest Coverage (TTM)0.39x
ROA (TTM)-63.19%
EV / EBITDA (TTM)13.41x
EPS Incl Extra (Annual)$-0.63
Current Ratio (Annual)1.27x
Quick Ratio (Quarterly)1.14x
3-Month Avg Trading Volume0.38M
52-Week Price Return-12.10%
Revenue / Employee (TTM)$31,457
Tangible BV / Share (Quarterly)$0.12
P/S Ratio (Annual)52.36x
Asset Turnover (Annual)0.04x
52-Week High$2.20
Operating Margin (5Y Avg)-576.31%
EPS Excl Extra (Annual)$-0.63
CapEx CAGR (5Y)-58.48%
Tangible BV CAGR (5Y)-40.70%
26-Week Price Return-11.90%
Quick Ratio (Annual)1.14x
13-Week Price Return10.00%
Total Debt / Equity (Annual)3.51x
Current Ratio (Quarterly)1.27x
Enterprise Value$162.38M
Revenue / Share Growth (5Y)-46.53%
Asset Turnover (TTM)0.06x
Book Value / Share Growth (5Y)-47.95%
Revenue / Employee (Annual)$19,660
Pretax Margin (Annual)-1764.51%
Cash / Share (Annual)$0.42
3-Month Return Std Dev100.44%
Gross Margin (5Y Avg)67.81%
Net Income / Employee (TTM)$-346,832
ROE (Last FY)-560.01%
Net Interest Coverage (Annual)5.98x
EPS Basic Excl Extra (Annual)$-0.63
P/FCF (TTM)52.99x
Receivables Turnover (TTM)8.56x
Total Debt / Equity (Quarterly)5.25x
EPS Incl Extra (TTM)$-0.63
Receivables Turnover (Annual)5.35x
ROI (TTM)-127.92%
P/S Ratio (TTM)32.73x
Pretax Margin (5Y Avg)-532.69%
Revenue / Share (Annual)$0.04
Tangible BV / Share (Annual)$0.12
Forward P/E33.00x
Price vs S&P 500 (52W)-36.47%
Year-to-Date Return-3.87%
5-Day Price Return-2.78%
EPS Normalized (Annual)$-0.63
ROA (5Y Avg)-34.95%
Net Profit Margin (Annual)-1764.51%
Month-to-Date Return-4.47%
Cash Flow / Share (TTM)$-0.81
EBITD / Share (Annual)$-0.68
Operating Margin (Annual)-1937.85%
LT Debt / Equity (Annual)2.51x
ROI (5Y Avg)-49.81%
LT Debt / Equity (Quarterly)3.49x
EPS Basic Excl Extra (TTM)$-0.63
P/TBV (Quarterly)18.20x
P/B Ratio (Annual)18.20x
Pretax Margin (TTM)-1103.12%
Book Value / Share (Annual)$0.12
Price vs S&P 500 (13W)1.75%
Beta1.09x
P/FCF (Annual)0.73x
Revenue / Share (TTM)$0.06
ROE (TTM)-658.91%
52-Week Low$1.03
vGradeD
gGradeF
mGradeC
vgmGradeD
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.13
4.13
4.13
4.13
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IPHAInnate Pharma S.A. ADS | D | F | C | $1.71 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Innate Pharma is a clinical-stage biotechnology company developing cancer immunotherapies using its proprietary ANKET platform and therapeutic antibodies to engage the innate immune system. The company generates revenue through research collaborations and licensing agreements with pharmaceutical partners. Its pipeline includes lacutamab, monalizumab, and several other advanced immunotherapy candidates.